Search clinical trials for: her2 positive non operable breast cancer

Total 129529 results

Exactis Innovation
Knight Therapeutics

Completed

RWD Study in HER2+ mBC Patients in Third-Line Therapy

Breast Cancer Stage IV

Canada
The Netherlands Cancer Institute
Tesaro, Inc.

Terminated

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

Breast Cancer

Netherlands
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Klus Pharma Inc.

Completed

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions

United States
SOLTI Breast Cancer Research Group

Terminated

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC (ARIANNA)

Breast Cancer

Spain
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Bladder Urothelial Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7

United States, Canada
Institut de cancérologie Strasbourg Europe

Recruiting

Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer (SIGHER)

HER2-positive Breast Cancer

France
KU Leuven
Novartis

Unknown

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer (IPSOC-mamma)

ER Positive, HER2 Negative Breast Cancer Neoplasms

Belgium
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

89ZrTrastuzumab Breast Imaging With Positron Emission Tomography

Breast Cancer

United States
Kimberly Blackwell

Terminated

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

HER2 Positive Untreated Metastatic Breast Cancer | Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer

United States
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

DESTINY Breast Respond HER2-low Europe

Metastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast Cancer

Austria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

Breast Cancer | HER2-positive Breast Cancer | Cardiotoxicity | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | HER2-positive Metastatic Breast Cancer

United States
Elevation Oncology

Terminated

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)

Metastatic Breast Cancer

Germany, Spain, United States, Austria, Belgium, Canada
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Breast Cancer

China
Fudan University

Recruiting

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

HER2-positive, Metastatic Breast Cancer

China
SUNHO（China）BioPharmaceutical CO., Ltd.

Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

HER2 Gene Mutation

China
Peregrine Pharmaceuticals

Withdrawn

A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Breast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
Azienda Ospedaliera Ordine Mauriziano di Torino

Unknown

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer (HERLAP)

Metastatic Breast Cancer

Italy
Seagen Inc.

Recruiting

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Carcinoma | Gallbladder Carcinoma | GEJ Adenocarcinoma

United States, Japan
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
University of Michigan Rogel Cancer Center

Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer

Breast Cancer

United States
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Breast Cancer

China
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
AstraZeneca
Austrian Breast and Colorectal Cancer Study Group (ABCSG)

Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)

Breast Cancer, Early Breast Cancer

United States, Spain, Italy, Korea, Republic of, Belgium, Canada, Poland, Portugal, United Kingdom, France, China, Germany, Japan, Mexico, Thailand, Hungary, Australia, Austria, Brazil, Colombia, Taiwan, Malaysia, Philippines, Romania, ... and more
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Solid Tumor

United States, Canada
Henan Cancer Hospital

Recruiting

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

HR Positive HER2 Negative Advanced Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
UNICANCER

Withdrawn

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer (OPTIGEN)

ER-positive Her2-negative Early Breast Cancer
SOLTI Breast Cancer Research Group

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Premenopausal Breast Cancer

Spain
University of Miami

Recruiting

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer (Free-HER)

Stage IV Breast Cancer | HER2-positive Metastatic Breast Cancer

United States
Institut Curie
Seagen Inc.

Recruiting

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer (TUC-TOC)

HER2-positive Breast Cancer

France
Yongsheng Wang
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer | Hormone Receptor Positive，HER2-negative Breast Cancer

China
Seagen Inc.

Completed

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

HER2 Positive Breast Cancer

United States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH)

Recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast

United States
West China Hospital

Recruiting

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Breast Cancer

China
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer (PYTHIA)

Metastatic Breast Cancer

United Kingdom, Belgium, Italy
Libbs Farmacêutica LTDA

Active, not recruiting

Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer (LB1802)

Breast Cancer

Brazil
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
National Cancer Institute (NCI)

Terminated

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Breast Carcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
University of Massachusetts, Worcester

Completed

IRS Proteins and Trastuzumab Resistance

Breast Cancer

United States
GlaxoSmithKline

Withdrawn

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Neoplasms, Breast
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
Taiwan Epidemiology Association

Unknown

Tw HER2 Positive Breast Cancer Productivity & Utility Study

HER2-positive Breast Cancer

Taiwan

Search clinical trials for: her2 positive non operable breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations